Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms

Abstract

The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine.

1 - 14 . (canceled) 
     
     
         15 . A method of inhibiting malignant cell migration in a host, comprising:
 administering into said host a migration-inhibiting effective amount of a composition comprising:
 (1) an anti-CXCL13 antibody, a fragment of an anti-CXCL13 antibody, an anti-CXCR5 antibody, or a fragment of an anti-CXCR5 antibody; and 
 (2) a pharmaceutically acceptable carrier, 
   wherein said malignant cell migration is carcinoma cell migration and wherein said composition is administered directly to tumor tissue.   
     
     
         16 . The method of  claim 15 , wherein said anti-CXCL13 antibody or said anti-CXCR5 antibody is a human antibody. 
     
     
         17 . The method of  claim 15 , wherein said anti-CXCL13 antibody or said anti-CXCR5 antibody is a humanized antibody. 
     
     
         18 . The method of  claim 15 , wherein said anti-CXCL13 antibody or said anti-CXCR5 antibody is a chimeric antibody. 
     
     
         19 . The method of  claim 15 , wherein said composition comprises both said anti-CXCL13 antibody and said anti-CXCR5 antibody. 
     
     
         20 . The method of  claim 15 , wherein said pharmaceutically acceptable carrier comprises a solid support. 
     
     
         22 . The method of claim  21 , wherein said solid support is a sponge or gauze. 
     
     
         23 . The method of  claim 15 , wherein said pharmaceutically acceptable carrier comprises liposomes. 
     
     
         24 . The method of  claim 15 , wherein said pharmaceutically acceptable carrier comprises microspheres. 
     
     
         25 . The method of  claim 15 , wherein said antibody is administered directly to tumor bed during an invasive procedure. 
     
     
         26 . The method of  claim 15 , wherein said anti-CXCL13 antibody, a fragment of an anti-CXCL13 antibody, an anti-CXCR5 antibody, or a fragment of an anti-CXCR5 antibody is administered at a dose range of 0.01-1000 mg/kg/day. 
     
     
         27 . The method of  claim 15 , wherein said anti-CXCL13 antibody or said anti-CXCR5 antibody is administered at a dose range of 0.1-100 mg/kg/day. 
     
     
         28 . The method of  claim 15 , wherein said pharmaceutically acceptable carrier is saline. 
     
     
         29 . The method of  claim 28 , wherein said saline is buffered saline. 
     
     
         30 . The method of  claim 15 , wherein said pharmaceutically acceptable carrier is glucose in saline. 
     
     
         31 . The method of  claim 15 , wherein said composition further comprises an antibody, or a fragment of an antibody, that binds to a chemokine or chemokine receptor selected from the group consisting of CCL1, CCL4, CCL17, CCL19, CCL21, CCL22, CCL25, CXCL12, CXCL16, CCR7, CCR8, CCR9, CXCR4, CXCR6, CX3CR1. 
     
     
         32 . A method of inhibiting carcinoma cell growth in a host, comprising:
 administering into said host a growth-inhibiting effective amount of a composition comprising:
 (1) an anti-CXCL13 antibody, a fragment of an anti-CXCL13 antibody, an anti-CXCR5 antibody, or a fragment of an anti-CXCR5 antibody; and 
 (2) a pharmaceutically acceptable carrier. 
   
     
     
         33 . The method of  claim 32 , wherein said composition comprises
 (1) an anti-CXCL13 antibody or a fragment of an anti-CXCL13 antibody;   (2) an anti-CXCR5 antibody or a fragment of an anti-CXCR5 antibody; and   (3) a pharmaceutically acceptable carrier.   
     
     
         34 . The method of  claim 32 , wherein said composition further comprises an antibody, or a fragment of an antibody, that binds to a chemokine or chemokine receptor selected from the group consisting of CCL1, CCL4, CCL17, CCL19, CCL21, CCL22, CCL25, CXCL12, CXCL16, CCR7, CCR8, CCR9, CXCR4, CXCR6, CX3CR1.